VKTX
Phase 3? Now we’re talking
Viking Therapeutics is pushing its oral obesity candidate, VK2735, into phase 3 testing. In biotech land, that’s the part where the science stops being a science fair project and starts looking like an actual shot at a drug, which is why traders perk up whenever a company crosses this line.
Why investors are paying attention
Obesity drugs have turned into the hottest club in pharma, and Viking wants a seat at the table. The market is already obsessed with who can build the next blockbuster pill, so even the hint of late-stage progress can give VKTX a nice little adrenaline shot.
The catch
Phase 3 is not a victory lap — it’s the expensive, nerve-wracking part. Data still has to hold up, safety has to behave, and the whole thing has to survive the biotech equivalent of a final exam with no cheat sheet.
Big picture
For investors, this is the classic biotech setup: promising science, big upside, and plenty of ways for things to go sideways. If VK2735 keeps advancing, Viking stays in the obesity-drug race; if not, the market will remember that hope is not the same thing as approval.